Home › NDC Lookup › RxCUI directory › RxCUI 1919512

2.4 ML durvalumab 50 MG/ML Injection [Imfinzi] — RxCUI 1919512

Name: 2.4 ML durvalumab 50 MG/ML Injection [Imfinzi] (RxCUI 1919512)
Creator: Brian Staiger, PharmD

RxNorm drug concept · Semantic branded drug

RxCUI 1919512 Semantic branded drug · SBD ● Current RxNorm concept 2 FDA products 2 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by Dr. Brian Staiger, PharmD

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI1919512

Official name2.4 ML durvalumab 50 MG/ML Injection [Imfinzi]

Concept typeSemantic branded drug (SBD)

RxNorm statusCurrent RxNorm concept

Also known as2.4 ML Imfinzi 50 MG/ML Injection; IMFINZI 120 MG in 2.4 ML Injection; IMFINZI 120 MG per 2.4 ML Injection

FDA products mapped2

Package NDCs mapped2

Reported Medicaid activity (SDUD)15,800 prescriptions · 48 state & territory Medicaid programs · latest period Q4 2025

RxNorm release07/06/2026

Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Durvalumab Injection: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist

No, Imfinzi works very differently from standard chemotherapy. Chemotherapy directly attacks dividing cells, including cancer cells. Imfinzi is an immunotherapy — it helps your own...
What exactly does Imfinzi do — is it like regular chemotherapy?
It really depends on whether Imfinzi is being given alongside chemotherapy or on its own. When Imfinzi is combined with certain chemo drugs, side effects like hair loss, nausea, an...
Will I lose my hair or feel very sick from this treatment?

📖 Read our full Durvalumab Injection guide →

🕸️ Concept Web — How 2.4 ML durvalumab 50 MG/ML Injection [Imfinzi] Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.

This page's concept 2.4 ML durvalumab 50 MG/ML Injection [Imfinzi] RxCUI 1919512 Semantic branded drug · SBD

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

Ingredients 1

The active substance itself — no strength, form, or brand attached yet.
- Durvalumab 1919503 IN
Brand names 1

The same medicine's trade names. A brand name alone says nothing about strength or form.
- Imfinzi 1919508 BN
Dose forms 6

The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
- Durvalumab Injection 1919506 SCDF
- Durvalumab Injectable Product 1919505 SCDG
- Durvalumab Injection [Imfinzi] 1919510 SBDF
- Imfinzi Injectable Product 1919511 SBDG
- Injection 1649574 DF
- Injectable Product 1151126 DFG
Clinical & branded drugs 3

Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
- 2.4 ML durvalumab 50 MG/ML Injection 1919507 SCD
- Durvalumab 50 MG/ML 1919504 SCDC
- Durvalumab 50 MG/ML [Imfinzi] 1919509 SBDC

Showing up to 8 concepts per family — 11 of 11 stored related concepts drawn.

These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

2.4 ML durvalumab 50 MG/ML Injection SCD · 1919507
Durvalumab 50 MG/ML SCDC · 1919504
Durvalumab Injection SCDF · 1919506
Durvalumab Injectable Product SCDG · 1919505

Brand-Name Concepts

Durvalumab 50 MG/ML [Imfinzi] SBDC · 1919509
Durvalumab Injection [Imfinzi] SBDF · 1919510
Imfinzi Injectable Product SBDG · 1919511
Imfinzi BN · 1919508

📦 FDA Products & Package NDCs

2 products · 2 package NDCs

2 package NDCs map to RxCUI 1919512 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.

Package NDC	Package	Brand / generic name	Labeler	Marketing start
00310-4500-12	1 VIAL in 1 CARTON (0310-4500-12) / 2.4 mL in 1 VIAL	IMFINZI	AstraZeneca Pharmaceuticals LP	2017-05-01
00310-4611-50	1 VIAL in 1 CARTON (0310-4611-50) / 10 mL in 1 VIAL	IMFINZI	AstraZeneca Pharmaceuticals LP	2017-05-01

Observed labelers: AstraZeneca Pharmaceuticals LP (2) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🧾 Billing Codes (HCPCS)

Medical billing codes (HCPCS "J-codes") that connect to this concept's packages — used mostly when a clinic or hospital bills for a drug it administers. Each code links to its full billing page.

Code	Descriptor	Mapped packages	Sources
J9173	Inj., durvalumab, 10 mg	2	CMS

⚠ A crosswalk is not coverage: an NDC↔HCPCS mapping does not guarantee any payer covers or pays the code. Always verify the current payer policy before billing.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7

openFDA export observedJul 14, 2026

RxNorm release07/06/2026

Methodology2026-07-full-catalog-v1

A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.

This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.